

CITATION REPORT

List of articles citing

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

DOI: 10.1016/j.xcrm.2020.100059
Cell Reports Medicine, 2020, 1, 100059.

Source: <https://exaly.com/paper-pdf/75835001/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
163	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. 2020 , 181, 104878		70
162	A Perspective on Organoids for Virology Research. <i>Viruses</i> , 2020 , 12,	6.2	8
161	Long-Term Modeling of SARS-CoV-2 Infection of Cultured Polarized Human Airway Epithelium. 2020 , 11,		38
160	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. 2020 , 13, 1187-1195		46
159	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,		4
158	Immune Response and COVID-19: A mirror image of Sepsis. 2020 , 16, 2479-2489		32
157	Antivirals for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11		4
156	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980		20
155	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. 2020 , 16, 2980-2991		16
154	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. <i>Nature</i> , 2020 , 585, 584-587	50.4	198
153	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. <i>Viruses</i> , 2020 , 12,	6.2	32
152	Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model. 2020 , 8,		2
151	Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience. 2020 , 120, 926-933		6
150	Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. 2020 , 287, 3664-3671		95
149	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527		52
148	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. 2020 , 9, 509-514		93
147	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. 2020 , 395, 1569-1578		2070

146	How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?. 2021 , 40, 72-107		19
145	The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. 2021 , 296, 100111		74
144	ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. 2021 , 56, 427-442.e5		110
143	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. 2021 , 14, 305-316		83
142	Conflicts over calcium and the treatment of COVID-19. 2021 , 9, 149-156		12
141	Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies. 2021 , 56, 90-93		
140	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287		11
139	In vitro characterisation of SARS-CoV-2 and susceptibility of domestic ferrets (<i>Mustela putorius furo</i>). 2021 ,		6
138	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. 2021 , 34,		61
137	Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. 2021 , 1322, 195-218		3
136	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. 2021 , 2, 100045		4
135	Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. 2021 , 78, 3565-3576		23
134	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. <i>Viruses</i> , 2021 , 13,	6.2	7
133	Berberine and Obatoclox Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro. <i>Viruses</i> , 2021 , 13,	6.2	24
132	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2.		1
131	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. 2021 ,		5
130	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. 2021 ,		0
129	SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. 2021 ,		67

128	Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. 2021 , 187, 105015		12
127	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. 2021 ,		
126	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. 2021 , 31, 325-337		29
125	Entry, egress and vertical transmission of SARS-CoV-2. 2021 , 13, 168-174		3
124	A novel, anatomy-similar in vitro model of 3D airway epithelial for anti-coronavirus drug discovery.		
123	Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. <i>Nature Communications</i> , 2021 , 12, 1726	17.4	32
122	Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS-CoV-2.		
121	Replicative fitness SARS-CoV-2 201/501Y.V1 variant in a human reconstituted bronchial epithelium.		2
120	SARS-CoV-2 infections in airway epithelial cells from smokers versus non-smokers.		
119	Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. 2021 , 26,		11
118	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. 2021 , 12, 638334		6
117	Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant.		3
116	In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease. <i>Viruses</i> , 2021 , 13,	6.2	11
115	SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity.		
114	Human-Based Advanced Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. 2021 , 8, 644678		10
113	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. 2021 , 44, 499-513		4
112	Towards More Predictive, Physiological and Animal-free Models: Advances in Cell and Tissue Culture 2020 Conference Proceedings. 2021 , 49, 93-110		3
111	SARS-CoV-2 Alpha, Beta and Delta variants display enhanced Spike-mediated Syncytia Formation.		3

110	SARS-CoV-2 infects an upper airway model derived from induced pluripotent stem cells. 2021 , 39, 1310-1321	5
109	Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D. 2021 , 13,	8
108	Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. 2021 , 184, 3192-3204.e136	16
107	Organoid Technology and the COVID Pandemic.	1
106	Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection. 2021 ,	3
105	SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. 2021 , 31, 847-860	24
104	Ultrastructural analysis of nasopharyngeal epithelial cells from patients with SARS-CoV-2 infection.	0
103	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. 2021 , 11,	44
102	SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. <i>Nature Communications</i> , 2021 , 12, 4354	17.4 39
101	Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. 2021 , 218,	33
100	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. 2021 , 12, e0141521	8
99	Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. <i>Viruses</i> , 2021 , 13,	6.2 4
98	Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium. 2021 , 12, e0085021	15
97	Optical nanoscopy reveals SARS-CoV-2-induced remodeling of human airway cells.	2
96	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. 2021 , 193, 105137	7
95	SARS-CoV-2 infected cells trigger an acute antiviral response mediated by Plasmacytoid dendritic cells in mild but not severe COVID-19 patients.	3
94	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. 2021 ,	8
93	Harness Organoid Models for Virological Studies in Animals: A Cross-Species Perspective. 2021 , 12, 725074	1

92	Ultra- and micro-structural changes of respiratory tracts in SARS-CoV-2 infected Syrian hamsters. 2021 , 52, 121	2
91	Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. 2021 , 6,	2
90	Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking. <i>Nano Today</i> , 2021 , 40, 101279	17.9 9
89	Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells. 2021 , 577, 146-151	4
88	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. 2021 , 13, 1-19	36
87	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. 2020 , 14, 641-648	97
86	Flagellin from <i>Pseudomonas aeruginosa</i> modulates SARS-CoV-2 infectivity in CF airway epithelial cells by increasing TMPRSS2 expression.	2
85	Long Period Modeling SARS-CoV-2 Infection of in Vitro Cultured Polarized Human Airway Epithelium. 2020 ,	1
84	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.	3
83	Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of the induction of IFN-mediated innate immune defences.	5
82	Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro.	2
81	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. 2020 , 16, e1009130	46
80	SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. 2021 , e108944	25
79	Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. <i>Nature Communications</i> , 2021 , 12, 5809	17.4 3
78	Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model.	0
77	A comparison of Remdesivir versus Au ²² Glutathione ¹⁸ in COVID-19 golden hamsters: a better therapeutic outcome of gold compound.	
76	SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication.	
75	Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. 2021 , 197, 105212	0

74	Real-time ultra-sensitive detection of SARS-CoV-2 by quasi-freestanding epitaxial graphene-based biosensor. 2022 , 197, 113803		4
73	A preview of selected articles. 2021 , 39, 1285-1288		
72	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. 2021 , 22, 304		0
71	Small airway dysfunction on impulse oscillometry and pathological signs on lung ultrasound are frequent in post-COVID-19 patients with persistent respiratory symptoms. <i>PLoS ONE</i> , 2021 , 16, e0260673,7		2
70	[Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia]. 2021 , 37, 1073-1076		
69	Treatments for COVID-19: Lessons from 2020 and new therapeutic options.. 2021 , 62, 43-59		4
68	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. 2021 , 16, 1341-1370		9
67	Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.		0
66	Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia.. 2022 , 29, 101187		0
65	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection , despite Eliciting a Prolonged Antiviral Response.. 2022 , e0343621		1
64	Asthma and COVID-19 Associations: Focus on IgE-Related Immune Pathology.. 2022 , 12,		1
63	The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates the immunoregulatory/inflammatory signals.. <i>IScience</i> , 2022 , 103854	6.1	0
62	Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database.. <i>BMC Infectious Diseases</i> , 2022 , 22, 1	4	5
61	Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern.. <i>Current Research in Virological Science</i> , 2022 , 3, 100019	3	3
60	Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract.. <i>Emerging Microbes and Infections</i> , 2021 , 1-26	18.9	0
59	Fast and real-time electrical transistor assay for quantifying SARS-CoV-2 neutralizing antibodies. <i>Communications Materials</i> , 2022 , 3,	6	2
58	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	120
57	Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2.. <i>Nature</i> , 2022 ,	50.4	15

56	Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review.. <i>Veterinary Pathology</i> , 2022 , 3009858211073678	2.8	0
55	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 7092	17.4	11
54	Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2). <i>PLoS ONE</i> , 2021 , 16, e0260958	3.7	6
53	Molecular network analysis of RNA viral infection pathway in diffuse- and intestinal-type gastric cancer. <i>Fundamental Toxicological Sciences</i> , 2022 , 9, 37-46	0.6	0
52	Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19.		3
51	Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells.. <i>Viruses</i> , 2022 , 14,	6.2	3
50	The effect of COVID-19 on nasal mucociliary clearance.. <i>Acta Oto-Laryngologica</i> , 2022 , 1-4	1.6	0
49	Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium.. <i>Nature Communications</i> , 2022 , 13, 1609	17.4	3
48	ICBS 2021: Looking Toward the Next Decade of Chemical Biology.. <i>ACS Chemical Biology</i> , 2022 ,	4.9	1
47	Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.		0
46	Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	1
45	Organoid and microfluidics-based platforms for drug screening in COVID-19.. <i>Drug Discovery Today</i> , 2021 ,	8.8	2
44	Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	3
43	A comparison of Remdesivir versus gold cluster in COVID-19 animal model: A better therapeutic outcome of gold cluster.. <i>Nano Today</i> , 2022 , 44, 101468	17.9	0
42	Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2.		0
41	Flagellin From Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMRSS2 Expression.. <i>Frontiers in Immunology</i> , 2021 , 12, 714027	8.4	1
40	In vitro tools for orally inhaled drug products: State of the art for their application in pharmaceutical research and industry and regulatory challenges. <i>In Vitro Models</i> , 2022 , 1, 29-40		
39	Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.. <i>PLoS Biology</i> , 2021 , 19, e3001065	9.7	2

38	Enhanced apoptosis as a possible mechanism to self-limit SARS-CoV-2 replication in porcine primary respiratory epithelial cells in contrast to human cells. <i>Cell Death Discovery</i> , 2021 , 7, 383	6.9	2
37	CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells.. <i>Cells</i> , 2022 , 11,	7.9	2
36	Application of exosomes for the alleviation of COVID-19-related pathologies. <i>Cell Biochemistry and Function</i> ,	4.2	1
35	Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7,	21	3
34	Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform.		0
33	Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study. <i>Indian Journal of Transplantation</i> , 2022 , 16, 216	0.2	
32	Cell and Animal Models for SARS-CoV-2 Research. <i>Viruses</i> , 2022 , 14, 1507	6.2	3
31	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 11,	8.9	0
30	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. 2022 , 11, 4464		1
29	Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants.		0
28	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. 2022 , 5,		0
27	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. 2022 , 10, 1639		0
26	NirmatrelvirRemdesivir association for non-hospitalized adults with COVID-19, point of view.		0
25	3D ex vivo tissue platforms to investigate the early phases of influenza A virus- and SARS-CoV-2-induced respiratory diseases. 1-30		0
24	Autoantibodies against type I IFNs in patients with critical influenza pneumonia. 2022 , 219,		1
23	The air-liquid interface model. 2022 , 51-72		0
22	Effect of Remdesivir Administration on Occurrence of Major Adverse Cardiac Events in Critically Ill COVID-19 Pneumonia: A Retrospective Observational Study. 2022 , 26, 993-999		0
21	Interactions Between Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human Nasal Epithelium.		1

20	Enterovirus D68 Infection in Human Primary Airway and Brain Organoids: No Additional Role for Heparan Sulfate Binding for Neurotropism.	0
19	Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. 7, 224	0
18	Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. 2022 , 18, e1010807	0
17	A novel antiviral formulation inhibits SARS-CoV-2 infection of human bronchial epithelium.	0
16	SARS-CoV-2 modulates inflammatory responses of alveolar epithelial type II cells via PI3K/AKT pathway. 13,	1
15	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.	3
14	Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine, in non-human primates.	0
13	Management of moderate severity outpatients with COVID -19 disease: Proposed criteria and algorithm for initiation of antiviral treatment.	0
12	Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact.	1
11	Inactivation of SARS-CoV-2 on Salt-Coated Surfaces: An In Vitro Study.	0
10	Pharmacologic Therapeutics for COVID-19. 2023 , 290-318	0
9	Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open label interventional study. 12,	1
8	In silico identification of microRNAs targeting the PPAR α Promising therapeutics for SARS-CoV-2 infection. 1-12	0
7	Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. 2023 , 14,	0
6	A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model. 2023 , 104,	0
5	Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. 2023 , 95,	0
4	An impact of age on respiratory syncytial virus infection in air-liquid-interface culture bronchial epithelium. 10,	0
3	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. 2023 , 15,	0

- 2 Immune Response in COVID-19-associated Acute Kidney Injury and Maladaptive Kidney Repair. **2023**, 10, ○
- 1 The Application of New Approach Methodologies in Respiratory Disease Research: Their Role in Improving Translational Medicine from Bench to Bedside. 026119292311703 ○